Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

ompound miravirsen, the International Nonproprietary Name (INN) or generic name for the compound formerly known as SPC3649.

Miravirsen, the first microRNA-targeted drug to enter human clinical trials, is a specific inhibitor of miR-122, a liver-specific microRNA that the Hepatitis C virus requires for replication. Unlike Hepatitis C therapies that directly target the virus, miravirsen works by removing a "helper" molecule (miR-122) that the virus needs in order to make new copies. Miravirsen is being studied in a Phase 1 trial multiple-ascending dose study in healthy volunteers and a Phase 2 study in patients infected with Hepatitis C is expected to begin in the second half of 2010.

Santaris Pharma A/S also has a broad range of drug discovery and development programs with its partners: Shire plc (lead candidates against up to five targets for rare genetic disorders), Pfizer (lead candidates against up to ten targets), GlaxoSmithKline (options to drug candidates from up to four viral disease programs) and Enzon Pharmaceuticals (lead candidates against eight cancer targets successfully delivered).

About Locked Nucleic Acid (LNA) Drug Platform

The LNA Drug Platform utilizing Santaris Pharma A/S proprietary LNA chemistry provides the key to delivering on the promise of RNA-targeted therapies today by addressing these concerns and overcoming the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity, which is only achievable with LNA-based drugs, allows this new class of drugs to potently and specifically inhibit RNA-targets in many different tissues without the need for complex delivery vehicles. LNA-based drugs are a promising new type of therapy that enables scientists to develo
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... orthopedic surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated ... in complete healing of an otherwise non-healing surgical knee wound. , The case ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
(Date:8/27/2015)... , August 27, 2015 GlassesOff (OTCBB: ... processing functions in the human vision system, announced today a ... point guard Chris Paul to develop a new ... want to improve their real-life on-court performance. Vision ... whether it is shooting a ball or blocking a pass. ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... that a second US laboratory is to open in Manhattan, Kansas in early ... partnership and long-term growth of research and development through collaboration with researchers from ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... flowers: in the nineties of the last century Norwegian ... in petunias inhibited its activity instead of reinforcing it ... was found that the mechanism is based on the ... the late nineties the Nobel prizewinners Andrew Fire and ...
... deal with the same problems, but they use different ... be difficult, if not impossible., A new $2.9 million ... National Science Foundation (NSF), will help bridge this problematic ... common problems a range of scientists face., The grant ...
... Quest Diagnostics,Incorporated (NYSE: DGX ), the nation,s leading ... is scheduled to speak,at the 2007 UBS Global Life ... 2007. The Quest Diagnostics presentation is scheduled to,begin at ... webcast live during the conference and will be,available to ...
Cached Biology Technology:Mechanism for the in-vivo transport of siRNA 2Mechanism for the in-vivo transport of siRNA 3CCMR gets $2.9M for training grad students in nanoscale science 2Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference 2
(Date:8/5/2015)... -- According to a new market research ... Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, Defense ... 2020", published by MarketsandMarkets, defines and segments the Physical ... The global PIAM Market is estimated to grow from ... at a CAGR of 14.9 % from 2014 to ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den ... bliver afholdt af BGI fra den 22. - 25. oktober ... Konferencen fejrer sin 10-års fødselsdag i år. Siden ... mest indflydelsesrige årlige møder på ,omik,-feltet, og er en ... ICG-10 fokuserer på nylige gennembrud og ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... hundreds, if not thousands, of suspected toxic substances every ... the brain, immune system, reproductive organs or hormones. Children ... requires product testing of most chemical compounds before they ... Riverside professor Carl Cranor argues in a new book, ...
... research effort designed to prevent the introduction of viruses to ... Chesapeake Bay watermen improve their bottom line by reducing the ... The findings, published in the journal Diseases of Aquatic ... in diseased and dying crabs likely occurs after the pre-molt ...
... scientists of the Technische Universitaet Muenchen (TUM) have been ... Prof. Stephan A. Sieber for the development of drugs ... million to study interactions between cellular components; 1.6 million ... a basic theory on elementary particles; Prof. Daniel Cremers ...
Cached Biology News:Legally poisoned 2Blue crab research may help Chesapeake Bay watermen improve soft shell harvest 2Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 2Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 3Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 4Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 5Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 6
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
1/4" to 1/8" Adapter for Reflectance Probe Holder...
... (GLP-1), C-terminal reactive. Cross-reacts fully with ... reactivity with the unamidated forms GLP-1(7-37) ... such as hGLP-2, glucagon, hGIP and ... is identical in all mammalian species ...
Biology Products: